Investor Relations

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

Recent Releases

Date Title and Summary
Toggle Summary Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer
HAMPTON, N.J. , June 24, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the appointment of Diane C. Young , M.D., as Senior Vice President, Chief Medical Officer, effective July 8, 2019 . Over the span of a 30 year career, Dr.
Toggle Summary Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma
--Evaluation of biomarkers for patient selection to be incorporated into expanded development program-- HAMPTON, N.J. , June 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today  presented results from the CDX-3379 clinical program at the 2019 American Society of Clinical

Upcoming Events

There are currently no events to display.

Featured Financial Reports

Show all

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline